Jun
9
2021
Upcoming webinar

Key considerations for maximizing LV and AAV production in transient transfection workflows

Wednesday 9th June 2021 8:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST

Recombinant adeno-associated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. 

Here, we present optimization strategies for generating higher AAV and LV titers in both adherent and suspension HEK 293 cells using the TransIT-VirusGEN® Transfection Reagent. In addition, we will introduce LV and AAV enhancers that further increase functional virus titers over previously optimized conditions and expand manufacturing capabilities for gene and cell therapies.

Attendees will learn:

  • Critical parameters for optimizing viral vector production and how small process changes can significantly impact titers
  • How VirusGEN® Transfection Kits supports gene and cell therapy researchers from R&D through commercial manufacturing 
  • How GMP-grade transfection formulations compare in terms of physical titers (GC/mL) and functional titers (TU/mL)

Leisha Kopp

Applications Scientist, Mirus Bio LLC

Leisha Kopp is an Applications Scientist at Mirus Bio LLC, a biotech company providing innovative transfection products to cell culture researchers worldwide. Leisha has over 15 years of molecular biology and mammalian cell culture experience in industrial labs, and her combined bench and business knowledge enables support of scientists in all stages of the drug discovery process - from R&D to commercial manufacturing. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in biotherapeutic antibody discovery and gene therapy.

Dr. Beth Larimore

Associate Director of Viral Vector Process Development, Bristol Myers Squibb

Dr. Beth Larimore is Associate Director of Viral Vector Process Development at Bristol Myers Squibb and is based in Seattle. A Bay Area native, Beth earned a BA in Biological Sciences at Cornell University and a PhD in Molecular and Cellular Biology at the University of Washington, where her doctoral work focused on the basic biochemistry of a tumor suppressor protein frequently mutated in human cancers. Beth started her industry career in purification of antibody therapeutics, but has worked on viral vector process development since 2014. She has held process development roles of increasing responsibility at Amgen, Immune Design, Nohla Therapeutics, and Juno Therapeutics/BMS. She is motivated by challenging scientific and engineering problems and feels privileged to contribute to novel, life-changing therapies.

23
Days
4
Hrs
42
Min

SPEAKERS

Leisha Kopp
Applications Scientist, Mirus Bio LLC
Leisha Kopp
Applications Scientist, Mirus Bio LLC
Dr. Beth Larimore
Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc
Dr. Beth Larimore
Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc